Teleflex (TFX) Q4 FY25 earnings call: guidance and Q&A

Confirm the split of $1.8 billion net proceeds between share repurchases and debt repayment.

Confirmed $1 billion for share repurchase authorization and $800 million for debt paydown, specifically $700 million for the deferred draw revolver (Bison acquisition) and $100 million for the general revolver.

“So it's $1 billion for the share repurchase. And that other $800 million, we are committed to paying down debt. So it will likely be the deferred draw revolver we put in place for the Bison acquisition of about $700 million, and then we'll put the other $100 million towards our revolver.”

asked by Michael Matson · answered by John Deren

Was any of the $50 million restructuring savings baked into the 2026 EPS guidance?

Yes, some savings from the current restructuring are baked into 2026 guidance. Additionally, there's line of sight on another $50 million in savings post-2026 from two restructurings (current and BIOTRONIK acquisition-related).

“Yes, the current restructuring has some savings in '26, that's already baked into the guidance, but we also have line of sight on $50 million post 2026 between the 2 restructurings.”

asked by Michael Matson · answered by John Deren

What's driving double-digit growth in Surgical ex-VBP, and how much VBP impact is left for 2026?

Growth driven by instrument portfolio (ear, nose, throat procedures) and ligation. VBP impact in China is still present but the lion's share is behind them. Automatic appliers also show growth opportunity in EMEA.

“Relative to Surgical, we've had some strength really across the portfolio. One standout has been our instrument portfolio, which has seen strength now for many quarters. We've got a refreshed instrument line there. And keep in mind, this instrument portfolio is really sort of aimed at ear, nose and throat procedures. That's been a really solid one. Of course, ligation continues to be a good driver of growth with the exception of China, where the VBP has been hitting.”

asked by Jayson Bedford · answered by Lawrence Keusch

What will the company look like in 2027 and beyond (sales growth, margin, EPS), and what qualities are sought in the new CEO?

No long-range plan for 2027, but significant EPS uplift expected due to stranded cost mitigation, debt paydown, and share buybacks. For CEO, focus is on experience with midsized, high-growth, global organizations in high-acuity hospital settings.

“I think when you're thinking about '27 though, and you think about the mid-single-digit growth, you look at '27 with our ability to take out the stranded costs, our ability to pay down a significant amount of debt and then buy back shares. I think you'll find, one, a really -- with your own math, a really nice underlying margin. And then I think with the share buyback, you're going to -- you should find yourself coming up with a significant uplift in the EPS. But I'll let you do that math, but I do not have guidance otherwise for 2027.”

asked by Shagun Singh Chadha · answered by John Deren

How are tariffs contemplated in the outlook, and what gets the operating margin back to mid-20s and above?

Plan contemplates tariffs expected before Supreme Court decision (~$35M total). Uncertainty remains, potential upside if tariffs are reduced. Operating leverage from mid-single-digit growth, combined with stranded cost mitigation, should quickly return margins to mid-20s.

“I think operating leverage, so if you start -- I won't tell you guys how to do your models, but if you start modeling out '27 with mid-single-digit growth and you start and you take out the stranded costs, the mitigation for the stranded cost, I would think you're quickly going to find yourself back in that mid-20s is what I would suggest.”

asked by Ravi Misra · answered by John Deren

Is a pro forma 2026 EPS of $9.50-$10 a fair way to think about the number if all benefits (stranded costs, debt paydown, share repurchases) were included?

Cannot confirm specific model, but acknowledged that with stranded cost mitigation, debt paydown, share buybacks, and mid-single-digit growth, "you'd find yourself closer in that -- in a $10 or more range."

“But I would think you'd find yourself closer in that -- in a $10 or more range is what I would think.”

asked by Matthew O'Brien · answered by John Deren

Update on BIOTRONIK integration, and is the 8% R&D as % of sales entirely due to BIOTRONIK or also increased investment in other RemainCo segments?

BIOTRONIK integration is going well, sales force integrated, talent retained. R&D step-up is partly due to BIOTRONIK's higher R&D, but also increased investment in interventional and vascular spaces, to a lesser extent in Surgical.

“So what I would tell you is, yes, BIOTRONIK came with a higher amount of R&D... There are much bigger investment opportunities in the interventional space. And so there's a -- in addition to what BIOTRONIK was spending, we have made some decisions to put in additional R&D resources for the interventional space. And then I think second to that would be in the vascular space, we've increased our R&D as well. Surgical, I would say, to a lesser extent.”

asked by Michael Polark · answered by John Deren

Will the company have enough "juice" to continue expanding margins once TSAs expire in a couple of years?

Yes, the goal is to fully mitigate stranded costs. Beyond that, operating leverage from revenue growth will contribute significantly to margin expansion. The company will continue to seek cost-saving initiatives.

“But our goal is to completely mitigate and offset those stranded costs. But keep in mind, the op margin profile with the growth profile should also contribute to some significant leverage over time to continue to move up that op margin on its own.”

asked by Travis Steed · answered by John Deren